FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003137831> ?p ?o ?g. }

• W2003137831 endingPage "173" @default.
• W2003137831 startingPage "170" @default.
• W2003137831 abstract "JRAAS 2001;2:170–3 Introduction Diabetic nephropathy accounts for the largest number of patients with end-stage renal disease (ESRD) in the UK, Europe, Japan and the United States. Despite growing evidence for the importance of blood pressure (BP) and glycaemic control in disease progression, the incidence of ESRD secondary to diabetic nephropathy continues to rise. The worldwide prevalence of diabetes is increasing steadily and the majority, in the developed world, have Type 2 diabetes. Hypertension and microalbuminuria (30–300 mg albumin/24 hours) are frequently present, even from the time of diagnosis. Microalbuminuria progresses over 5–10 years to proteinuria (>300 mg of protein/24 hours) in 20–40% of patients. Persistent proteinuria is the hallmark of diabetic nephropathy and is accompanied by a progressive decline in glomerular filtration rate (GFR). Heavy proteinuria and co-existing hypertension both accelerate the rate of progression to ESRD. Microalbuminuria is a strong predictor of cardiovascular morbidity and mortality in Type 2 diabetics. Indeed, the leading cause of death in diabetics is cardiovascular disease. Type 2 diabetics have the same excess risk of myocardial infarction (MI) as non-diabetics who have previously had a myocardial infarct. Furthermore, the combination of diabetes and hypertension is associated with an approximately 4-fold increase in cardiovascular risk when compared with the non-diabetic normotensive population. Treatment strategies in diabetics aim to slow the onset and progression of renal disease and other microvascular complications and to reduce the associated excess cardiovascular risk. In Type 1 diabetics with proteinuria or microalbuminuria, blockade of the renin-angiotensin system (RAS) with angiotensin-converting enzyme inhibitors (ACE-I) improves renal outcome. ACE-I are renoprotective, in that they afford protection against progressive proteinuria and renal insufficiency, which is independent of, and probably additive to, their BP-lowering effect. There is now a consensus opinion that ACE-I, when well tolerated, should be used as first line therapy in this group.Their role in Type 2 diabetics, however, is not yet fully established. In 1993, Ravid reported that the ACE-I, enalapril, stabilised plasma creatinine and urinary albumin excretion in 94 normotensive,Type 2 diabetics with microalbuminuria and normal renal function. More recently, the MICRO-HOPE study demonstrated that ramipril reduced cardiovascular mortality and early renal disease progression in individuals with both Type 1 and Type 2 diabetes. This effect appeared to be greater than might be attributable to the decrease in BP in the ramipril-treated group, although the potential contribution of BP reduction in this study remains contentious. Other studies have compared ACE-I with other antihypertensives, with varying outcomes on the observed rates of diabetic complications and mortality. The UKPDS trial stratified treatment intensities in hypertensive Type 2 diabetics, specifying BP targets of below either 150/80 mmHg or 180/105 mmHg. These targets were achieved with either an ACE-I, captopril, or a beta-blocker, atenolol, as the main treatment. In the lower BP group, there was a reduction in the risk of death related to diabetes, progression of diabetic nephropathy and deterioration in visual acuity. However, further analysis of the outcome data in the lower blood pressure group showed no difference between those treated with the ACE inhibitor or beta blocker. Both of these agents inhibit the renin-angiotensin system and there was no comparison, in this study, with a regimen that did not block the renin-angiotensin system. Despite the number of trials conducted to date, there remains controversy over which agent, if any, offers superior renal or cardiovascular protection in Type 2 diabetics. The question also remains as to whether blockade of the RAS will confer similar benefits in Type 2 as in Type 1 diabetics. Furthermore, it may be that BP reduction itself is more important than the treatment used to achieve it.These important questions and unresolved issues have provided the background for three prospective clinical trials, which evaluated the effect of angiotensin II receptor blockers (ARBs) on cardiovascular and renal outcomes, specifically in Type 2 diabetics.The results of these trials have now been published simultaneously in the New England Journal of Medicine." @default.
• W2003137831 created "2016-06-24" @default.
• W2003137831 creator A5030429171 @default.
• W2003137831 creator A5090468155 @default.
• W2003137831 date "2001-09-01" @default.
• W2003137831 modified "2023-10-14" @default.
• W2003137831 title "Renoprotection in Type 2 diabetes: blockade of the renin-angiotensin system with angiotensin II receptor blockers" @default.
• W2003137831 cites W1604542334 @default.
• W2003137831 cites W1986924251 @default.
• W2003137831 cites W2044773944 @default.
• W2003137831 cites W2045161455 @default.
• W2003137831 cites W2050456578 @default.
• W2003137831 cites W2056976690 @default.
• W2003137831 cites W2098154750 @default.
• W2003137831 cites W2110837983 @default.
• W2003137831 cites W2137408480 @default.
• W2003137831 cites W2138119952 @default.
• W2003137831 cites W2138670606 @default.
• W2003137831 cites W2145252145 @default.
• W2003137831 cites W2147804563 @default.
• W2003137831 cites W2158665637 @default.
• W2003137831 cites W2312999996 @default.
• W2003137831 cites W2331274940 @default.
• W2003137831 cites W2615684303 @default.
• W2003137831 cites W2975364463 @default.
• W2003137831 cites W3021250193 @default.
• W2003137831 cites W3156148333 @default.
• W2003137831 cites W3198570063 @default.
• W2003137831 cites W4242344507 @default.
• W2003137831 cites W4244182132 @default.
• W2003137831 cites W4296980881 @default.
• W2003137831 cites W4323238053 @default.
• W2003137831 doi "https://doi.org/10.3317/jraas.2001.023" @default.
• W2003137831 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11881118" @default.
• W2003137831 hasPublicationYear "2001" @default.
• W2003137831 type Work @default.
• W2003137831 sameAs 2003137831 @default.
• W2003137831 citedByCount "1" @default.
• W2003137831 countsByYear W20031378312021 @default.
• W2003137831 crossrefType "journal-article" @default.
• W2003137831 hasAuthorship W2003137831A5030429171 @default.
• W2003137831 hasAuthorship W2003137831A5090468155 @default.
• W2003137831 hasBestOaLocation W20031378311 @default.
• W2003137831 hasConcept C126322002 @default.
• W2003137831 hasConcept C170493617 @default.
• W2003137831 hasConcept C185592680 @default.
• W2003137831 hasConcept C198710026 @default.
• W2003137831 hasConcept C2778468042 @default.
• W2003137831 hasConcept C2908929049 @default.
• W2003137831 hasConcept C2910553456 @default.
• W2003137831 hasConcept C71924100 @default.
• W2003137831 hasConcept C84393581 @default.
• W2003137831 hasConcept C98274493 @default.
• W2003137831 hasConceptScore W2003137831C126322002 @default.
• W2003137831 hasConceptScore W2003137831C170493617 @default.
• W2003137831 hasConceptScore W2003137831C185592680 @default.
• W2003137831 hasConceptScore W2003137831C198710026 @default.
• W2003137831 hasConceptScore W2003137831C2778468042 @default.
• W2003137831 hasConceptScore W2003137831C2908929049 @default.
• W2003137831 hasConceptScore W2003137831C2910553456 @default.
• W2003137831 hasConceptScore W2003137831C71924100 @default.
• W2003137831 hasConceptScore W2003137831C84393581 @default.
• W2003137831 hasConceptScore W2003137831C98274493 @default.
• W2003137831 hasIssue "3" @default.
• W2003137831 hasLocation W20031378311 @default.
• W2003137831 hasLocation W20031378312 @default.
• W2003137831 hasOpenAccess W2003137831 @default.
• W2003137831 hasPrimaryLocation W20031378311 @default.
• W2003137831 hasRelatedWork W1989591433 @default.
• W2003137831 hasRelatedWork W1994259586 @default.
• W2003137831 hasRelatedWork W2077998387 @default.
• W2003137831 hasRelatedWork W2126797993 @default.
• W2003137831 hasRelatedWork W2149410839 @default.
• W2003137831 hasRelatedWork W2151226843 @default.
• W2003137831 hasRelatedWork W2162471541 @default.
• W2003137831 hasRelatedWork W2190649397 @default.
• W2003137831 hasRelatedWork W2345841378 @default.
• W2003137831 hasRelatedWork W2744890335 @default.
• W2003137831 hasVolume "2" @default.
• W2003137831 isParatext "false" @default.
• W2003137831 isRetracted "false" @default.
• W2003137831 magId "2003137831" @default.
• W2003137831 workType "article" @default.